Residual Effects of Low-Dose Sublingual Zolpidem on Highway Driving Performance the Morning after Middle-of-the-Night Use

Annemiek Vermeeren, PhD1; Eric F.P.M. Vuurman, PhD1; Tim R.M. Leufkens, PhD1; Cees J. Van Leeuwen, MD1; Anita C.M. Van Oers1; Eugene Laska, PhD2; Salvador Rico, MD3; Frank Steinberg, DO3; Thomas Roth, PhD4

1Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands; 2Nathan Kline Institute for Psychiatric Research, Orangeburg, NY and New York University, Langone School of Medicine, New York, NY; 3Transcept Pharmaceuticals, Inc., Point Richmond, CA; 4Henry Ford Hospital Sleep Disorders and Research Center, Detroit, MI

Study Objective: To evaluate next-morning driving performance after middle-of-the-night use of zolpidem 3.5 mg in a buffered sublingual formulation (ZST).

Design: Single-center, four-period, randomized, double-blind, placebo-controlled, crossover study.

Setting: Maastricht University, The Netherlands.

Participants: Forty healthy volunteers (20 females).

Interventions: Single dose of ZST administered in the middle of the night at 3 and 4 h before driving, zopiclone 7.5 mg at bedtime 9 h before driving, and placebo.

Measurements: Performance in a 100-km standardized highway driving test in normal traffic measuring standard deviation of lateral position (SDLP) — an index of weaving. Drug-placebo changes in SDLP > 2.5 cm were considered to reflect clinically relevant driving impairment.

Result: For ZST, Max McNemar symmetry analyses showed that the proportion of drivers classified as impaired was increased 3 h after dosing (P < 0.012), but not 4 h after dosing. Mean increases in SDLP from placebo, although statistically significant, were small (1.46 cm [P < 0.0001] at 3 h and 0.83 cm [P = 0.0174] at 4 h). The morning after zopiclone, 45% of the drivers were classified as impaired with a mean increase in SDLP of 2.46 cm (P < 0.0001). There were no significant sex differences in effects of ZST and zopiclone.

Conclusion: Zolpidem 3.5 mg in a buffered sublingual formulation has a minimal risk of impairing driving performance in the morning ≥ 4 hours after middle-of-the night use. When taken 3 hours before driving, the drug may have impairing effects so caution should be exercised if medication is taken other than as indicated.

Clinical Trial Information: ClinicalTrials.gov Identifier: NCT01106859; Trial Name: Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet; http://clinicaltrials.gov/ct2/show/NCT01106859.

Keywords: Driving, hypnotics, sex, zopiclone, zolpidem sublingual

Introduction

A large segment of the general population experiences middle-of-the-night (MOTN) insomnia, i.e., nocturnal awakenings followed by difficulties resuming sleep. Telephone surveys in the United States and Europe have shown that about one-third of the respondents reported waking up during the night for multiple nights per week, and between 25% and 43% of those (7.7% and 15.2% of all respondents) reported difficulty resuming sleep. Telephone surveys in the United States and Europe have shown that about one-third of the respondents reported waking up during the night for multiple nights per week, and between 25% and 43% of those (7.7% and 15.2% of all respondents) reported difficulty resuming sleep, providing there are no other sleep environments. As a consequence, those individuals have a high risk of daytime sleepiness, front-line prescribed hypnotic drugs (ZOP and ZST) are therefore considered relatively safe by prescribing physicians and have become the most commonly prescribed hypnotic drugs in Europe and the United States, respectively. Nonetheless, these drugs can cause next-day impairment when taken as indicated or especially when taken against prescribing information. Several experimental studies have shown that bedtime doses of ZOP 7.5 mg have effects on driving that are on average comparable to those of blood alcohol concentrations (BACs) of 0.05 %.12 Similarly, zolpidem 10 mg used in the MOTN was found to have effects on driving comparable to BACs of 0.08 %.12 When taken in the MOTN, 5 h before driving, its average effects were found to be comparable to BACs of 0.08 %.12 Similarly, zolpidem 10 mg used in the MOTN was found to have effects on driving comparable to BACs between 0.05 and 0.08 %.12

In November 2011, buffered sublingual formulations of zolpidem (ZST), in doses of 1.75 mg for adult women and 3.5 mg for adult men, were approved in the United States for use as needed to treat insomnia characterized by MOTN awakening followed by difficulty returning to sleep, providing there are no other sleep environments. As a consequence, those individuals have a high risk of daytime sleepiness, front-line prescribed hypnotic drugs (ZOP and ZST) are therefore considered relatively safe by prescribing physicians and have become the most commonly prescribed hypnotic drugs in Europe and the United States, respectively. Nonetheless, these drugs can cause next-day impairment when taken as indicated or especially when taken against prescribing information. Several experimental studies have shown that bedtime doses of ZOP 7.5 mg have effects on driving that are on average comparable to those of blood alcohol concentrations (BACs) of 0.05 %.12 Similarly, zolpidem 10 mg used in the MOTN was found to have effects on driving comparable to BACs of 0.08 %.12 When taken in the MOTN, 5 h before driving, its average effects were found to be comparable to BACs of 0.08 %.12 Similarly, zolpidem 10 mg used in the MOTN was found to have effects on driving comparable to BACs between 0.05 and 0.08 %.12

In November 2011, buffered sublingual formulations of zolpidem (ZST), in doses of 1.75 mg for adult women and 3.5 mg for adult men, were approved in the United States for use as needed to treat insomnia characterized by MOTN awakening followed by difficulty returning to sleep, providing there are no other sleep environments. As a consequence, those individuals have a high risk of daytime sleepiness, front-line prescribed hypnotic drugs (ZOP and ZST) are therefore considered relatively safe by prescribing physicians and have become the most commonly prescribed hypnotic drugs in Europe and the United States, respectively. Nonetheless, these drugs can cause next-day impairment when taken as indicated or especially when taken against prescribing information. Several experimental studies have shown that bedtime doses of ZOP 7.5 mg have effects on driving that are on average comparable to those of blood alcohol concentrations (BACs) of 0.05 %.12 Similarly, zolpidem 10 mg used in the MOTN was found to have effects on driving comparable to BACs of 0.08 %.12 When taken in the MOTN, 5 h before driving, its average effects were found to be comparable to BACs of 0.08 %.12 Similarly, zolpidem 10 mg used in the MOTN was found to have effects on driving comparable to BACs between 0.05 and 0.08 %.12

In November 2011, buffered sublingual formulations of zolpidem (ZST), in doses of 1.75 mg for adult women and 3.5 mg for adult men, were approved in the United States for use as needed to treat insomnia characterized by MOTN awakening followed by difficulty returning to sleep, providing there are no other sleep environments. As a consequence, those individuals have a high risk of daytime sleepiness, front-line prescribed hypnotic drugs (ZOP and ZST) are therefore considered relatively safe by prescribing physicians and have become the most commonly prescribed hypnotic drugs in Europe and the United States, respectively. Nonetheless, these drugs can cause next-day impairment when taken as indicated or especially when taken against prescribing information. Several experimental studies have shown that bedtime doses of ZOP 7.5 mg have effects on driving that are on average comparable to those of blood alcohol concentrations (BACs) of 0.05 %.
at least 4 h of time in bed remaining. Studies in patients with insomnia have shown that ZST 3.5 mg significantly shortens sleep latencies after nocturnal awakenings as compared with placebo (PBO).17,18

ZST delivers and facilitates absorption of a part of the dose through the buccal mucosa, while the remainder is swallowed and absorbed in the gastrointestinal tract. A pharmacokinetic study in 24 healthy young volunteers found that peak plasma concentrations after single doses of ZST are on average reached in approximately 38 min, after which they declined with an elimination half-life of approximately 2.5 h.19 ZST plasma levels of 20 to 25 ng/mL were reached within 20 min and maintained for up to 4 h, after both 1.75 mg and 3.5 mg doses. In comparison, after use of ZST in its conventional oral dosage form of 10 mg immediate-release tablets for adults, peak plasma concentration of 125 ng/mL is generally reached within 1 to 2 h, and decline to 20 to 25 ng/mL in 8 h.20,21 Studies in patients with insomnia have shown that ZST 3.5 mg significantly shortens sleep latencies after nocturnal awakenings as compared with PBO.17,18

Based on its formulation, pharmacokinetics, and dose, it was expected that ZST 3.5 mg would have no clinically relevant residual effects 4 h or more after intake. In line with this expectation, no significant residual sedation or psychomotor impairment was found in patients using subjective ratings of daytime alertness and performance on a digit symbol substitution task.27 In addition, a study comparing the effects of single daytime doses of 1.0, 1.75, and 3.5 mg ZST and PBO in healthy volunteers on a battery of psychomotor and memory tests showed that recovery to predrug levels of psychomotor performance occurred within 4 h after the two highest doses of ZST.19 Subjective ratings of sedation were no different from PBO after 3 h, and effects on memory were no longer found 1 h after administration. Together the results of these studies suggest that ZST 3.5 mg could be administered up to about 4 h before awakening without having residual effects on psychomotor performance in the morning. However, it is important to assess its effects on car driving the morning after MOTN dosing to further characterize morning function.

The current study was therefore designed to measure the morning effects of ZST 3.5 mg on driving performance, using an on-the-road driving test that was standardized in the 1980s.22,23 The primary outcome variable of this test is standard deviation of lateral position (SDLP), which is a measure of road-tracking error or the amount of “weaving” of the car. It is a reliable characteristic of individual driving performance; the test-retest reliability of unmedicated drivers is r = 0.85 (range: 0.7-0.9).22-24 It is sensitive to the effects of many sedating agents including alcohol, with blood concentrations as low as 0.035%.25 The test has been calibrated with increasing doses of alcohol sufficient to raise BACs to 0.12%. The alcohol calibration curve demonstrates that drinkers’ mean SDLP rises exponentially with increasing BACs, and that the mean increase in SDLP from PBO at a BAC of 0.05% is approximately 2.5 cm. This effect has often been used as a criterion level to quantify effects of drugs other than alcohol. Drug-induced mean increases in SDLP that are significantly different from PBO and exceed this criterion are considered clinically relevant.26 Significant increases in SDLP below this criterion are generally considered minor, and if the 95% confidence interval (CI) is below the criterion as well, the drug is considered unlikely to produce relevant impairment.

To evaluate the probability that a drug will increase the risk of impaired driving rather than simply affecting mean performance, another approach evaluates the proportion of subjects whose change in SDLP during the drug condition compared with the PBO condition is sufficiently large to imply potential risk of impaired driving. Although such a cutoff point for individual performance changes in SDLP has not been formally validated, a first threshold could be set at the same criterion as used for the mean increase in SDLP, i.e., increases exceeding 2.5 cm. It would be concluded that the drug has no effect on driving if changes in SDLP following drug treatment are random, in that numbers of subjects showing changes in SDLP above +2.5 cm and below -2.5 cm are not different. If symmetry analysis shows that significantly more subjects show changes above +2.5 cm than below -2.5 cm, the drug increases the risk of impaired driving performance.27

The objective of this study was to assess the effects of ZST 3.5 mg on highway driving at 4 h after dosing (consistent with patient instructions for appropriate use) and 3 h after dosing (inconsistent with patient instructions). ZOP 7.5 mg taken at bedtime 9 h before driving (consistent with patient instructions for appropriate use) was included in the study as an active control to demonstrate assay sensitivity as has been the case in other studies.3,7-14 Driving impairment was evaluated by symmetry analyses of proportions of impaired and improved drivers,27 and by comparing means and 95% CIs of drug-PBO changes in SDLP. In addition, sex differences in treatment effects were evaluated (post hoc), given the sex differences in zolpidem pharmacokinetics.28,29

METHODS

Subjects
Forty subjects (20 men, 20 women) were recruited via advertisements placed in local newspapers. Healthy volunteers age 21 to 64 y were eligible to enroll if they possessed a valid driving license, had an average driving experience of at least 3,000 km/y over the past 3 y, a body mass index of no more than 29 kg/m², and normal vision (corrected or uncorrected). Subjects were required to be in good health as confirmed by their medical history questionnaire, physical examination, electrocardiogram, and laboratory tests (blood chemistry and hematology).

Subjects who met any of the following criteria were excluded from the study: history or current evidence of any clinically significant physical, mental, or sleep disorders, alcoholism, or drug abuse; pregnancy or breastfeeding; use of medication known to affect sleep-wake function or driving performance or hepatic drug metabolism; participation in any other clinical trial, oral surgery, tooth extraction, or piercing of the lip or tongue within 60 days prior to screening; excessive smoking (> 10 cigarettes a day); and overconsumption of alcohol (> 21 drinks per w) or caffeine (> 6 cups of coffee per day). All subjects were tested for drug use (amphetamine, benzodiazepines, cannabis, cocaine, MDMA [3,4-methylenedioxy-N-methylamphetamine; Ecstasy], and opiates), and females for pregnancy at prestudy screening and at the start of each test session.
During participation, subjects were required to abstain from prescription and nonprescription medications. They also had to refrain from smoking and/or consuming caffeine and alcohol from the time of arrival at the site on treatment days, until the completion of all tests the next day. In addition, alcoholic drinks, grapefruit juice, and grapefruit were not permitted from 24 h before arrival, and caffeine and food were not permitted from 4 h prior to arrival.

Ethical approval was obtained from the Medical Ethics Committee of Maastricht University, and all volunteers provided written informed consent prior to enrollment. The study was carried out in compliance with the current revision of the Declaration of Helsinki, and the International Conference on Harmonization Guidelines for Good Clinical Practice.

Design and Treatments

The study was conducted according to a randomized, double-blind, PBO-controlled, four-way crossover design. The four treatment conditions were single oral doses of ZST 3.5 mg administered in the MOTN 4 h before the start of the morning driving test; ZST administered in the MOTN 3 h before the start of the driving test; ZOP 7.5 mg administered at bedtime, 9 h before the start of the driving test; and PBO. These treatment conditions will be referred to as ZST 4 h, ZST 3 h, ZOP, and PBO, respectively, hereafter. Bedtime drug administration (23:15) was followed by PBO MOTN administration (04:15 or 05:15) and vice versa, or PBO at both times (Figure 1). Treatment was blinded using a double-dummy technique with two PBOs; a capsule to match ZOP for bedtime dosing, and a sublingual tablet to match ZST for MOTN dosing. Order of treatment conditions and time of MOTN awakening in ZOP and PBO was balanced over subjects using a Williams design. Washout periods between treatments were at least 3 days.

Standardized Highway Driving Test

Driving performance was assessed using a standardized highway driving test recording SDLP as a measure of driver vehicle control (Figure 2).

In this test, subjects operate a specially instrumented vehicle for approximately 1 h over a 100-km (61 mile) primary highway circuit, accompanied by a licensed driving instructor having access to dual controls (brakes and accelerator). The subjects’ task is to drive with a steady lateral position between the delineated boundaries of the slower (right) traffic lane, while maintaining a constant speed of 95 km/h (58 mph). Subjects may deviate from those instructions only to pass a slower vehicle, and to leave and re-enter the highway at the turnaround point. During the drive, the vehicle’s speed and lateral distance to the left lane line are continuously recorded. These signals are digitized at a rate of 4 Hz and stored on an onboard computer disk file for later preprocessing and analysis. Preprocessing consists of offline visual inspection of all data by trained processors (blinded as to treatment condition) to mark data segments that reveal signal loss or disturbances such as passing maneuvers and turnaround point. The preprocessed dataset is then used to calculate means and variances of lateral position and speed of clean (unmarked) data. The primary outcome variable is SDLP in cm.

Procedure

Within 2 w before the first treatment condition, subjects slept 1 night in the same facilities as during treatment conditions, to overcome possible sleep disturbances associated with sleeping in an unfamiliar environment. In the evening preceding their habituation night, subjects were individually trained to perform the driving test.

On treatment days, subjects arrived at the sleeping facility at approximately 22:00 and their eligibility and compliance with study restrictions was verified by questioning, urine screens for drugs of abuse and pregnancy, breath testing for alcohol, and measurement of vital signs. Four subjects were treated on the same night and tested the following day with 5 min difference between their activities. At 23:15 the first subject ingested a first
dose of medication or PBO in the presence of an investigator and retired to bed. At 04:15 or 05:15 the investigator awakened the subject by a telephone call, administered the second dose, and instructed the subject to resume sleeping (Figure 1). At 07:30 the investigator awakened the subjects in the same manner. Following toileting and dress, subjects were provided a standardized light breakfast without caffeine and transported to the highway. The driving test started at approximately 08:15, i.e., 3 or 4 h after MOTN dosing. After completion of the driving test subjects were transported home by study personnel.

Within 10 days after the last treatment, subjects’ health and well-being were confirmed by questioning them about adverse events, and by physical examination and laboratory tests (blood chemistry and hematology).

Statistical Analyses

To detect an asymmetry in the distribution of the difference between the drug and PBO SDLP, a Max McNemar test was used. The test examines the difference in the proportions of impaired drivers and improved drivers following drug use using a generalized sign test over all relevant thresholds. Symmetry implies that the probability of improvement over use using a generalized sign test over all relevant thresholds. Of impaired drivers and improved drivers following drug was used. The test examines the difference in the proportions of impaired drivers and improved drivers following drug use using a generalized sign test over all relevant thresholds. SDLP changes of three tests that were terminated prematurely are indicated by triangles.

RESULTS

A total of 44 volunteers were screened for this study, with 40 enrolled (20 males, 20 females). All enrolled subjects completed the study between June and September 2010. Mean ± standard deviation (SD) age was 37.3 ± 14.8 y. Thirty-nine subjects were white, and one was mixed race. Mean ± SD body mass index was 23.2 ± 2.4 kg/m². Mean ± SD body weight was 79 ± 8 kg for males and 65 ± 8 kg for females.

Proportions of Impaired and Improved Drivers

Individual subject and mean changes from PBO in SDLP for males and females in each treatment condition are shown in Figure 3.

Two 23-y-old female subjects stopped driving in a total of three driving tests, because the driving instructor judged them too drowsy to safely continue. Both subjects were stopped in ZOP (after 97% and 67% completion of the drive), and one of them was also stopped in ZST 3 h (again after 67% completion). None of the subjects was stopped prematurely in ZST 4 h or PBO. SDLP scores for the prematurely terminated tests were calculated from the data collected until the termination of each ride, and all were increased by more than 2.5 cm compared to their PBO scores (Figure 3).

Symmetry analyses of SDLP changes showed that driving performance was significantly more frequently impaired than improved in ZOP and ZST 3 h, but not in ZST 4 h. Symmetry analyses of SDLP changes showed that driving performance was significantly more frequently impaired than improved in ZOP and ZST 3 h, but not in ZST 4 h. At the third hour, there were 20 subjects whose absolute change from ZST to PBO in SDLPs exceeded 1.5. The Max McNemar test result was 10.88 (P < 0.002). At the fourth hour, there were 15 subjects whose SDLP exceeded 1.5 and the Max McNemar test result was not significant. Table 1 displays results of tests of symmetry at the specific cut points 2.5, 3.0 and 2.0 cm based on a McNemar test. According to the primary criterion (i.e., a change in SDLP of ≥ 2.5 cm, or test terminated due to drowsiness) 18 subjects
Effects of Sublingual Low-Dose Zolpidem on Driving—Vermeeren et al

Mean Changes in SDLP Scores

Mean ± SD SDLP scores were 15.88 ± 3.14, 16.71 ± 3.34, 17.33 ± 3.57, and 18.34 ± 4.01 in PBO, ZST 4 h, ZST 3 h, and ZOP, respectively (Table 2).

Repeated-measures analysis of variance showed that the differences between treatments were significant (P < 0.0001). Mean changes from PBO in SDLP in ZST 4 h and ZST 3 h were +0.83 cm (P = 0.0174) and +1.46 cm (P < 0.0001), respectively. Although these changes are statistically significantly different from PBO, the upper limits of the 95% CIs were below the threshold of 2.5 cm. In ZOP, the mean change in SDLP was +2.46 cm (P < 0.0001). As expected, the 95% CI included the criterion for impairment.

Means and changes in SDLP scores were comparable for males and females (Table 2). Post hoc analysis showed no significant effect of sex (P = 0.52) or treatment by sex interaction (P = 0.86).

Safety

A total of 22 adverse events were spontaneously reported by 14 of 40 subjects (35%). After ZST administration, 17.5% of the subjects reported adverse events that were all minor in nature, except one episode of moderate nausea in the ZST 4 h group. The most frequently reported adverse events were minor headache and somnolence. Headache was reported by 7.5% of subjects after administration of ZST, and by 2.5% of subjects after administration of PBO or ZOP. Somnolence was reported by 5.0% of subjects after administration of each active treatment and by 2.5% of subjects after administration of PBO. Fatigue was reported by 5.0% of subjects receiving PBO treatment.

There were no serious adverse events, and no clinically significant changes in physical examination findings or

Table 1—Symmetry analysis of proportions impaired and improved drivers in each treatment condition, at three thresholds of impairment

<table>
<thead>
<tr>
<th>Threshold</th>
<th>Treatment</th>
<th>Group</th>
<th>n</th>
<th>Impaired n (proportion)</th>
<th>Improved n (proportion)</th>
<th>McNemar</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5 cm</td>
<td>ZST 4 h</td>
<td>All</td>
<td>40</td>
<td>5 (0.125)</td>
<td>1 (0.025)</td>
<td>2.67</td>
<td>0.2188</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>20</td>
<td>2 (0.100)</td>
<td>0</td>
<td>-</td>
<td>0.5000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Males</td>
<td>20</td>
<td>3 (0.150)</td>
<td>1 (0.050)</td>
<td>-</td>
<td>0.6250</td>
</tr>
<tr>
<td></td>
<td>ZST 3 h</td>
<td>All</td>
<td>40</td>
<td>10 (0.250)</td>
<td>1 (0.025)</td>
<td>7.36</td>
<td>0.0117</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>20</td>
<td>6 (0.300)</td>
<td>1 (0.050)</td>
<td>-</td>
<td>0.1250</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Males</td>
<td>20</td>
<td>4 (0.200)</td>
<td>0</td>
<td>-</td>
<td>0.1250</td>
</tr>
<tr>
<td></td>
<td>ZOP</td>
<td>All</td>
<td>40</td>
<td>16 (0.450)</td>
<td>0</td>
<td>18.00</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>20</td>
<td>10 (0.500)</td>
<td>0</td>
<td>-</td>
<td>0.0002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Males</td>
<td>20</td>
<td>6 (0.300)</td>
<td>0</td>
<td>-</td>
<td>0.0078</td>
</tr>
<tr>
<td>2.0 cm</td>
<td>ZST 4 h</td>
<td>All</td>
<td>40</td>
<td>6 (0.150)</td>
<td>1 (0.025)</td>
<td>3.57</td>
<td>0.1250</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>20</td>
<td>13 (0.650)</td>
<td>2 (0.100)</td>
<td>8.07</td>
<td>0.0074</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Males</td>
<td>20</td>
<td>19 (0.950)</td>
<td>0</td>
<td>19.00</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>3.5 cm</td>
<td>ZST 4 h</td>
<td>All</td>
<td>40</td>
<td>2 (0.050)</td>
<td>0</td>
<td>2.00</td>
<td>0.5000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Females</td>
<td>20</td>
<td>7 (0.350)</td>
<td>0</td>
<td>7.00</td>
<td>0.0156</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Males</td>
<td>20</td>
<td>14 (0.700)</td>
<td>0</td>
<td>14.00</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

ZOP, zopiclone 7.5 mg; ZST, zolpidem 3.5 mg sublingual formulation.

Table 2—Mean (standard deviation) standard deviation of lateral position scores in each treatment condition and results of analysis of variance of drug-placebo contrasts

<table>
<thead>
<tr>
<th></th>
<th>SDLP, cm</th>
<th>Change from PBO, cm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (95% CI)</td>
</tr>
<tr>
<td>All (n = 40)</td>
<td>PBO 15.88 (3.14)</td>
<td>0.83 (0.1-1.5)</td>
</tr>
<tr>
<td></td>
<td>ZST 4h 16.71 (3.34)</td>
<td>1.46 (0.8-2.1)</td>
</tr>
<tr>
<td></td>
<td>ZST 3h 17.33 (3.57)</td>
<td>2.46 (1.8-3.1)</td>
</tr>
<tr>
<td></td>
<td>ZOP 18.34 (4.01)</td>
<td>2.46 (1.8-3.1)</td>
</tr>
<tr>
<td>Females (n = 20)</td>
<td>PBO 15.6 (2.9)</td>
<td>0.9 (-0.1-0.2)</td>
</tr>
<tr>
<td></td>
<td>ZST 4h 16.5 (3.3)</td>
<td>1.7 (0.8-2.6)</td>
</tr>
<tr>
<td></td>
<td>ZST 3h 17.3 (3.2)</td>
<td>2.4 (1.5-3.4)</td>
</tr>
<tr>
<td></td>
<td>ZOP 18.1 (3.9)</td>
<td>2.4 (1.5-3.4)</td>
</tr>
<tr>
<td>Males (n = 20)</td>
<td>PBO 16.2 (3.4)</td>
<td>0.8 (-0.2-0.0)</td>
</tr>
<tr>
<td></td>
<td>ZST 4h 16.9 (3.5)</td>
<td>1.2 (0.2-2.3)</td>
</tr>
<tr>
<td></td>
<td>ZST 3h 17.4 (4.0)</td>
<td>2.5 (1.5-3.6)</td>
</tr>
<tr>
<td></td>
<td>ZOP 18.6 (4.2)</td>
<td>2.5 (1.5-3.6)</td>
</tr>
</tbody>
</table>

CI, confidence interval; PBO, placebo; SD, standard deviation; SDLP, standard deviation of lateral position; ZOP, zopiclone 7.5 mg; ZST, zolpidem 3.5 mg sublingual formulation.
laboratory measures identified during the study. There were no sex differences in safety measures and adverse event reporting.

**DISCUSSION**

The aim of the current study was to assess the effects of ZST 3.5 mg on driving at 4 h after MOTN dosing (consistent with patient instructions for appropriate use) and 3 h after MOTN dosing (inconsistent with patient instructions). Results showed that when ZST was taken 4 h before driving, there was no statistically significant difference in the proportions of impaired and improved drivers. The mean SDLP at that time was significantly higher than PBO, but the overall increase was small (0.83 cm), and the 95% CI was well below the 2.5 cm threshold for impairment (95% CI, 0.1-1.5 cm). When ZST was taken later in the night, 3 h before driving, a significantly greater proportion of subjects were impaired than improved (25% versus 2.5%). Yet, the mean increase in SDLP was still small (1.46 cm) with a 95% CI below the 2.5 cm threshold for impairment (95% CI, 0.8-2.1 cm). This indicates that although the effects of ZST administered 3 h before driving were statistically significant, they were less severe than those of alcohol at the legal limit for driving, and those following bedtime doses of most intermediate- and long-acting hypnotic drugs. Overall, the data support that driving at least 4 h after taking ZST 3.5 mg, consistent with labeling instructions, does not negatively affect driving performance. Driving within 3 h of taking ZST 3.5 mg, however, may result in a negative effect on driving performance. The negative effect on driving performance is not surprising, given the previous data on the duration of action of ZST on a variety of performance tests. The results support current driving dosing guidelines indicating that ZST should only be used when at least 4 h of time in bed are anticipated.

Compared with the effects of MOTN administration of ZST in its conventional dose of 10 mg, the effects of the low-dose buffered formulation are clearly reduced. ZST 10 mg produced mean increases in SDLP at 4 and 5 h after MOTN administration of 3.8 cm and 3.5 cm, respectively, which is well above the 2.5 cm criterion for impairment, and just below the effects found for alcohol when BACs are 0.08% (4.1 cm). Effects of ZOP 7.5 mg clearly demonstrated assay-sensitivity in the current study. It significantly increased mean SDLP by 2.46 cm and was associated with 45% impaired drivers, as defined by a change in SDLP of more than 2.5 cm. The observed mean increase in SDLP is comparable to that found in previous studies using the same driving test, indicating that the subjects in the current study showed normal sensitivity to drug effects. The proportion of impaired drivers was consistent with mean change. For example, assuming a normal distribution of change, an observed mean of 2.5 cm would be accompanied by about half of the subjects worsening by more than the 2.5-cm threshold for impairment, a smaller proportion falling in the indifference zone and a still smaller proportion improving their driving by more than 2.5 cm.

Overall, ZST 3.5 mg was well tolerated, and there were no sex differences in the types or rates of adverse events. Nonetheless, one female subject had to discontinue the driving test after 67% completion due to excessive drowsiness after use of ZST 3 h before driving. The same subject was also stopped from driving at the same point because of drowsiness after bedtime use of ZOP, suggesting she may have been sensitive to the sedative effects of this class of drugs. One other female subject was stopped from driving because of excessive drowsiness after use of ZOP. Associated changes in SDLP scores relative to PBO all exceeded the primary impairment criterion of 2.5 cm, but absolute SDLP scores of the terminated rides were still within the normal range of PBO conditions (i.e., between 10 cm and 30 cm). These data are in line with the results of symmetry analyses and mean changes in SDLP, showing that driving can be significantly impaired after use of ZOP and ZST 3 h before driving.

In contrast to the lack of sex differences in ZST’s effects in the current study, a recent paper reporting a post hoc sex analysis of data from a study by Verster and colleagues showed that driving performance in women was more impaired than in men after MOTN use of ZST 10 mg and 20 mg. A major difference between these studies is the dose. As sex-related differences in performance are potentially related to differences in drug concentrations, it seems that the differences in concentrations after 3.5 mg may be too small to produce significant differences in performance between men and women.

It is not unusual that driving tests are terminated prematurely. The overall percentage of tests terminated prematurely in the current study (1.9% of a total of 160) is comparable to that found in other studies. A recent review of 47 papers reporting 50 Dutch clinical trials using the same driving test showed that on average approximately 3.1% of the tests are stopped, not only after drug treatment (4.1%) but also after PBO (0.7%). Thus, the percentage of tests terminated in the current study is below average. The review concludes that the decision to stop driving is not a good correlate of objective driving performance.

The results of this study are in line with previous findings that ZST 3.5 mg no longer produces clinically relevant sedation or performance impairment at 4 h or more after MOTN dosing. In a pharmacokinetic/pharmacodynamic study with healthy volunteers by Roth and colleagues, ZST 3.5 mg impaired performance in tests of digit symbol substitution, symbol copying, choice reaction time, and word learning within the first 3 h, but not after that. Although these tests are useful for initial screening of relevant impairment, based on the results of this study, it appears that they do not reliably predict more subtle effects on driving performance, such as those found between 3 and 4 h after dosing in the current study.

**Limitations**

The use of healthy volunteers instead of patients with insomnia could be seen as a limitation of the current study. An important reason normal volunteers are enrolled is to facilitate comparisons to previous driving studies, which were virtually all conducted with normal volunteers. More importantly, a recent study comparing the effects of ZOP on driving in patients with insomnia and healthy volunteers suggests that healthy volunteers may be more sensitive to the residual effects. Thus, studying drug effects in healthy volunteers minimizes the risk of failing to detect clinically relevant impairment associated with use of a drug. To determine the modifying effects of insomnia diagnosis and the interaction as well as other comorbid disorders and concomitant medication, additional data from studies in patient populations are needed. This study intended to determine the impairment potential of the...
drug alone, as compared with that of other drugs; for example, ZOP 7.5 mg at bedtime, or ZST 10 mg in the MOTN.

Another point for discussion may be the criteria used for clinically relevant impairment in this study. We used a newly developed statistical method to evaluate impairment rates using improvement rates as an internal control over all relevant thresholds as the defining criterion.32,35,36 Because there is no widely accepted criterion for driving impairment based on any other drug, alcohol is still the most important benchmark. In studies evaluating the residual effects of hypnotic drugs, ZOP 7.5 mg is increasingly used as a reference because its effects are reliable and moderately severe, in the sense that the magnitude of effects on driving is comparable to those of alcohol concentrations of 0.05%, which is the legal limit for driving a car in most countries.37

In conclusion, the results of this study suggest that ZST 3.5 mg has a minimal risk of impairing driving performance in the morning, 4 h or more after MOTN use. When taken 3 to 4 h before driving, the drug may have minor impairing effects, so caution should be exercised at that time. Patients should be instructed accordingly.

ABBREVIATIONS
BAC, blood alcohol concentration
CI, confidence interval
h, hour(s)
km, kilometers
mph, miles per hour
MOTN, middle of the night
PBO, placebo
SD, standard deviation
SDLP, standard deviation of lateral position
y, year(s)
ZOP, zopiclone
ZST, zolpidem sublingual formulation

ACKNOWLEDGMENTS
The authors thank Henk Brauers, Jo Gorissen, Hans Sleebe, Bert Adriaens, Irma Brauers, Anique van Dorp, Natalie Valle Guzman, Lizzy Vuurman, ZsaZsa Weerts, Bart Wagemans, Sander Huisman, Iwan de Jong, Francis Palmen, Odile Schoffelen, and Arno Skrabanja (Maastricht University) for their expertise in carrying out this study; Elizabeth Li (Pharmaceuticals Ltd) and Tam Vo and Gautam Bijur (Excerpta Medica) for providing editorial assistance with the manuscript.

DISCLOSURE STATEMENT

REFERENCES


10. Mets MA, de Vries JM, de Senerpont Domis LM, Volkerts ER, Olivier B, Verster JC. Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. Sleep 2011;34:1327-34.


34. Verster JC, Roth T. Predicting psychopharmacological drug effects on actual driving (SDLP) from psychometric tests measuring driving-related skills. Psychopharmacology 2012;220:293-301.

